LONDON (Alliance News) - Tiziana Life Sciences said its anti-CD3 monoclonal antibody foralumab was featured in a review published online, and due to be published in peer-reviewed medical journal Immunotherapy.
The company is currently developing foralumab in the areas of "graft vs host disease" and ulcerative colitis, an inflammatory bowel disease. Graft versus host disease is a medical complication arising after the receipt of transplanted tissue from a genetically different person.
The review article was authored by Howard Weiner, who joined Tiziana's scientific advisory board earlier in the year, along with Chantal Kuhn of Harvard Medical School.
It highlights the unique attributes of foralumab, Tiziana said, and also demonstrated that the oral or nasal administration of an anti-CD3 monoclonal antibody has "significant potential" for the treatment of autoimmune and inflammatory diseases.
Shares in Tiziana were untraded Thursday morning at 144.31 pence.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.